-
Study aim
-
To determine the effect of adding rosuvastatin to the standard Helicobacter pylori eradication regimen on the eradication rate.
-
Design
-
A phase 3, randomized, double blind, placebo controlled, parallel clinical trial will be conducted in 208 patients with one to one allocation. Block randomization with variable block sizes of 4 and 6 will be performed using Random Allocation Software.
-
Settings and conduct
-
The study will be conducted at Emam Khomeini Hospital in Ardabil. Rosuvastatin and placebo will be packaged and coded by an independent pharmacist. Participants and treating physicians will be blinded to group allocation, and the data analyst will remain blinded until completion of the final analysis.
-
Participants/Inclusion and exclusion criteria
-
Patients aged 18 years or older with upper gastrointestinal symptoms and Helicobacter pylori infection confirmed by stool antigen testing will be included. Major exclusion criteria include previous gastric surgery or eradication therapy, use of antibiotics, proton pump inhibitors, histamine receptor blockers, or nonsteroidal anti inflammatory drugs during the previous month, allergy to study antibiotics, gastrointestinal malignancy or bleeding, pregnancy, and breastfeeding.
-
Intervention groups
-
The intervention group will receive levofloxacin 500 milligrams daily, esomeprazole 40 milligrams every 12 hours, amoxicillin 2 grams daily, and rosuvastatin 20 milligrams daily for 14 days. The control group will receive the same standard regimen plus matching rosuvastatin placebo.
-
Main outcome variables
-
Helicobacter pylori eradication one month after completion of treatment, assessed by stool antigen testing.